Crescent Biopharma, Inc.(CBIO)Earnings Date, History & Expected Move

Next report date, beat rate and options-implied move

Next report

Nov 4, 2026

CBIO is scheduled to report on Nov 4, 2026. Analysts expect EPS of -$0.73.

Next report

Nov 4, 2026

In 11 days

EPS beat rate

60%

3 of 5 quarters (+1 not counted)

Avg move after earnings

±3.3%

Up 60% of the time · last 5

Options-implied move

—

No reliable options quote yet

Add to calendar

EPS: Actual vs Estimate

Reported EPS against the consensus estimate, last 6 quarters.

Green beat or met, red missed, amber sources differ.

Stock Reaction After Earnings

Close-to-close move in the first session that reflected each report.

Dashed lines mark the average actual move (±3.3%).

Did the stock rise after good news?

The next-day move after each of its last 3 EPS beats and 1 misses.

When it beat expectations

3 reports

▲ Rose 3×

When it missed expectations

1 report

▼ Fell 1×

Report by report

Jul '26
Beat
▲ +1.7%
Apr '26
Beat
▲ +6.8%
Nov '25
Beat
▲ +5.4%
Jul '25
Missed
▼ -1.4%

Clear beats and misses with a known reaction only. What counts as a beat

After an EPS beat

+4.6%

average next-day move · up 100% of 3 times

After an EPS miss

—

Not enough quarters yet

Was CBIO's earnings move already priced in?

CBIO's move in the month before each of its last 5 reports, against what it did after.

Avg move in the month before

-2.4%

last 5 reports

Higher before the report

60%

of the time

After a run-up of 3%+

Fell 33%

3 reports, avg +3.7%

How the run-up is measured (a move of 5% or more counts as large).

Before vs after each report

Grey: the month before each of the last 5 reports. Green or red: the day after.

Past reports only. How the run-up is measured

What the history says

CBIO has beaten EPS estimates in 3 straight quarters (quarters where our data sources disagree are skipped).

CBIO earnings history

Last 6 reported quarters with the stock's reaction.

Swipe sideways to see every column →

Report date	Time	EPS est.	EPS actual	Surprise	1-day move	3-day move
Jul 30, 2026	Before open	-$0.64	-$0.62	+3.1%	+1.69%	+0.68%
Apr 29, 2026	After close	-$0.95	-$0.70	+26.3%	+6.83%	-14.42%
Feb 26, 2026	Before open	-$2.82	-$4.92	sources differ	-1.12%	-10.33%
Nov 6, 2025	Before open	-$1.38	-$1.37	+0.7%	+5.39%	+5.47%
Jul 31, 2025	Before open	-$3.68	-$3.72	-1.1%	-1.43%	-6.03%
Jun 18, 2025	After close	-$3.64	-$18.39	-405.2%	—	—

Consensus for the next report: EPS -$0.73, revenue $318,750.00.

CBIO Earnings FAQ

Answers computed from Crescent Biopharma, Inc.'s reported history

CBIO is scheduled to report on Nov 4, 2026. Analysts expect EPS of -$0.73.

Over the last 5 quarters with a usable EPS surprise, CBIO beat the consensus estimate 3 times (60%), missed 2 and landed in line 0. It has beaten estimates in each of the last 3 counted quarters. 1 quarter where our data sources disagree on beat versus miss are shown but not counted.

Across its last 5 quarters with a measured reaction, CBIO moved an average of ±3.3% in the first session after reporting. It closed higher 60% of the time; the largest gain was 6.8% and the largest drop -1.4%.

Across its last 5 quarters with price data, CBIO moved an average of -2.4% in the 20 trading sessions before reporting and was higher in 60% of them. After a run-up of 3% or more (3 quarters), it fell the next day 33% of the time, averaging +3.7%. This describes past reports; it is not a forecast.

How we calculate these numbers · CBIO: 6 reported quarters, latest Jul 30, 2026. Information only, not investment advice.

Earnings this week

Every report this week with expected moves.

Biggest expected earnings moves

Options-implied vs historical move, ranked.